중추신경계 바이오마커 시장 : 바이오마커 유형별, 용도별, 최종 용도별, 세계 예측(2024-2032년)

Global Central Nervous System Biomarkers Market will grow at an 8.1% CAGR between 2024 and 2032, owing to advancements in biomarker research and their adoption in drug discovery and clinical trials. These biomarkers offer crucial insights into disease mechanisms, treatment responses, and patient stratification, enhancing the development of targeted therapies. As pharmaceutical companies increasingly rely on biomarkers to streamline drug development processes and improve treatment outcomes, the demand for innovative biomarker solutions for neurological disorders will rise, contributing to market expansion.

For instance, in March 2024, Alamar Biosciences unveiled the Ultra-High Sensitivity NULISAseq(TM) CNS Disease Panel 120 and NULISAqpcr(TM) PTau-217 Assays. The NULISAseq CNS Disease Panel 120 enables multiplexed protein analysis for neurological disorders, while the NULISAqpcr pTau-217 Assay (ALZpath antibody) focuses on dementia research.

The central nervous system biomarkers industry is classified based on biomarker type, application, end-use, and region.

The efficacy biomarker segment will witness a considerable rise by 2032 due to the demand for biomarkers that provide insights into treatment effectiveness for neurological disorders. Efficacy biomarkers offer crucial data on therapeutic responses and disease progression, aiding in personalized medicine approaches. As the focus shifts towards precision medicine, pharmaceutical companies and clinicians rely on these biomarkers to develop targeted therapies. With their vital role in treatment optimization, the efficacy biomarker segment will maintain dominance in the central nervous system biomarkers market.

The central nervous system biomarkers market size from the drug discovery and development segment will see a notable surge during 2024 and 2032. As researchers strive for innovative treatments for neurological disorders, biomarkers play a pivotal role in drug discovery. These markers provide insights into disease mechanisms, treatment responses, and patient stratification crucial for developing effective therapies. Pharmaceutical companies rely on biomarkers to streamline clinical trials and optimize drug development processes. With an increasing focus on precision medicine, the drug discovery and development segment will stand at the forefront, driving advancements in neurological treatments.

Asia Pacific central nervous system biomarkers industry will capture a noteworthy CAGR between 2024 and 2032, driven by the region's growing healthcare infrastructure and rising incidence of neurological disorders. Countries like China and India are key contributors to this growth, with their large population base and increasing investment in healthcare. Additionally, advancements in biomarker research and diagnostics in APAC bolster market expansion. With a focus on improving neurological disease management, Asia Pacific will emerge as a substantial contributor to the central nervous system biomarkers market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neurological disorders
    • 3.2.1.2 Increasing advancements in biomarker discovery technologies
    • 3.2.1.3 Rising government initiatives and policies
    • 3.2.1.4 Increasing use of CNS biomarkers
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with CNS biomarker tests and diagnostics
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Biomarker Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Safety biomarker
• 5.3 Efficacy biomarker
• 5.4 Validation biomarker
• 5.5 Other biomarkers

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Disease diagnosis
• 6.3 Drug discovery and development
• 6.4 Personalized medicines
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Diagnostic laboratories
• 7.4 Academic & research institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 bioMerieux
• 9.2 Bio-Rad Laboratories, Inc.
• 9.3 F. Hoffmann-La Roche Ltd
• 9.4 G-Biosciences
• 9.5 Illumina, Inc.
• 9.6 Merck KGaA
• 9.7 Myriad Genetics, Inc.
• 9.8 Novartis AG
• 9.9 PerkinElmer Inc.
• 9.10 Siemens Healthineers AG
• 9.11 Sysmex Corporation
• 9.12 Thermo Fisher Scientific Inc.